India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Divi’s Labs: Oral Wegovy Scale-Up, New Optionality

HD Fire Protect IPO: A High-Margin Export Franchise

Tonbo Imaging IPO: A Full-Stack Global Defence Electronics Platform

Hyundai Motor India: From a Disrupted Q1 to Record Q2 Volumes — Can the 2030 Roadmap Rebuild Growth?

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Sahajanand Medical Technologies / Equity Bottom-Up

Sahajanand Medical Technologies (2585275D IN)

<ul>
<li>SMT plans to open its IPO on 15 October 2026 through an offer for sale (OFS) of approximately 1.38 crore equity shares, with no fresh capital raised by the issuer.</li>
<li>FY26 revenue from operations reportedly reached Rs. 1,210.5 crore, up 18.1%; PAT reached Rs. 69.1 crore versus Rs. 25.15 crore in FY25. </li>
<li>SMT has meaningful international exposure, a clinically specialised product portfolio and a growing structural-heart business.</li>
</ul>


SMT plans to open its IPO on 15 October 2026 through an offer for sale (OFS) of approximately 1.38 crore equity shares, with no fresh capital raised by the issuer.
FY26 revenue from operations reportedly reached Rs. 1,210.5 crore, up 18.1%; PAT reached Rs. 69.1 crore versus Rs. 25.15 crore in FY25. 
SMT has meaningful international exposure, a clinically specialised product portfolio and a growing structural-heart business.


Sahajanand Medical Technologies IPO: Global Stent Franchise, Emerging Structural Heart Opportunity